Home/Pipeline/Platform-Derived Pipeline

Platform-Derived Pipeline

Oncology (unspecified)

Discovery/Pre-clinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Discovery/Pre-clinical

Status

Active

Company

Phinomics

About Phinomics

Phinomics is pioneering a novel approach to precision oncology by targeting the 'hidden 50%' of cancer biology, specifically extrachromosomal circular DNA (ecDNA). The company's proprietary platform isolates and decodes ecDNA and cryptic proteins, integrating this data with other molecular layers via explainable AI to build a comprehensive model of cancer's decision-making architecture. This approach aims to dramatically improve target discovery and biomarker prediction, addressing the high failure rate in oncology drug development. Phinomics is a private, pre-clinical stage company building its therapeutic pipeline and platform capabilities from its San Diego headquarters.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active
DDX3 Inhibitor (Oncology)	Lead Discovery Siena	Discovery	Active